In the multicenter , double-blind , randomized , event-driven , phase III SERAPHIN ( Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome ) trial , patients with symptomatic PAH were randomized ( @:@:@ ) to receive placebo or @ mg or @ mg of macitentan .